KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV)
Get a source-linked, educational explanation from this profile.
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV) is listed as regenerative / aesthetic multi-peptide blend.
- •Skin quality and wound-healing research
- •Soft-tissue (tendon, ligament, muscle) repair research
- •Inflammatory skin and gut research
- •Hair and collagen support (GHK-Cu component)
- •Post-procedure recovery
- •Calming of inflammatory signaling (KPV component)
Regulatory status: Not FDA-approved in any form. FDA placed BPC-157 and thymosin beta-4 fragments on its compounding Category 2 list (significant safety concerns), so compounding pharmacies generally cannot supply them. TB-500 is WADA-prohibited; the other components may fall under WADA's non-approved substances clause..
Structure & Properties
Compound: KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV); also known as KLOW, KLOW peptide blend, KLOW stack, GLOW + KPV, Klow blend.
Pharmacologic class: Regenerative / Aesthetic Multi-Peptide Blend.
Known delivery routes: Subcutaneous (unstudied as a blend).
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
A fixed-ratio research-market blend of four peptides, each studied separately: BPC-157 (a 15-amino-acid gastric peptide fragment that supports blood-vessel growth, tendon cell migration and gut-lining protection in animal studies); TB-500 (a fragment of thymosin beta-4 that binds actin to promote cell migration and wound closure); GHK-Cu (a copper-binding tripeptide that stimulates collagen and glycosaminoglycan production and modulates many tissue-repair genes); and KPV (the C-terminal tripeptide of alpha-MSH, which dampens NF-kB inflammatory signaling and is taken up by gut cells via PepT1). The combination itself has never been studied as a unit.
- •Faster wound and tendon healing in animal studies (BPC-157, TB-500)
- •Collagen and skin-repair gene activity (GHK-Cu, mostly cell and topical data)
- •Reduced gut and skin inflammation in animal models (KPV)
- •Single injection replaces four separate vials
Human Research
Evidence grade: Pre-clinical / Observational
Evidence is primarily preclinical or observational; human effectiveness and long-term safety are not established.
- Sikiric P et al. BPC 157, a body protection compound: review. Curr Pharm Des. 2018;24:1990-2001.
- Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110:774-80.
- Goldstein AL et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12:37-51.
- Malinda KM et al. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999;113:364-8.
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19:1987.
- Pickart L et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108.
- Luger TA et al. New insights into the functions of α-MSH and related peptides in the immune system. Ann N Y Acad Sci. 2003;994:133-40.
- Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134:166-78.
- Xiao B et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017;25:1628-40.
- U.S. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 list, includes BPC-157 and thymosin beta-4 fragments).
- World Anti-Doping Agency. Prohibited List (S0 non-approved substances; S2 includes thymosin β4 and derivatives).
Laboratory Research
No human trials of the KLOW combination. Each component has animal and cell research; GHK-Cu has topical cosmetic human data, and thymosin beta-4 has small early human trials for wounds and eye injury. Evidence for injecting the four together is extrapolated, not tested.
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
No studied schedule. Community use is once daily, often in the evening, given as one subcutaneous injection.
Potential interactions and combinations to avoid
- •Active or suspected cancer — several components promote blood-vessel growth
- •Taking BPC-157, TB-500, GHK-Cu or KPV separately at the same time — doubles up the same ingredients
- •High-dose vitamin C at the same moment as GHK-Cu — may disturb the copper complex
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •No human safety data for the combination
- •Fixed ratio — a reaction cannot be traced to one ingredient, and doses cannot be adjusted separately
- •Injection-site stinging or blue-tinged welts from copper (GHK-Cu)
- •Theoretical concern with cancer because several components promote blood-vessel growth
- •Research-chemical supply — purity, sterility and labeled amounts often unverified
Contraindications
- •Active cancer or history of cancer
- •Pregnancy or breastfeeding
- •Wilson's disease or copper sensitivity
- •Competitive athletes subject to WADA testing
- •Under 18 years of age
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- •Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- •Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: No established human dose for the blend. Commonly sold vial: BPC-157 10 mg + TB-500 10 mg + GHK-Cu 50 mg + KPV 10 mg; community protocols are anecdotal, not studied.
Frequency: Not established — community use is typically once daily
Cycling: No evidence-based cycle exists. Community protocols commonly run 8–12 weeks followed by about 4 weeks off; this is anecdotal.
Subcutaneous
Community use: once daily; no studied schedule.
Insulin syringe (U-100). Rotate abdominal sites. GHK-Cu often stings — inject slowly.
No human data for the blend; fixed ratios prevent adjusting one ingredient.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Clinician-guided wound, skin or physical-therapy care
- •Gentle skincare and sun protection
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Educational only. The four-peptide combination has never been tested in people.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
What is KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV)?
In plain words
KLOW is a mix of four lab-made peptides sold together in one vial. Three of them (BPC-157, TB-500 and GHK-Cu) are studied for healing skin and tissues, and the fourth (KPV) for calming inflammation in the skin and gut. Each piece has some animal or lab research, but nobody has tested the four together in people, so its safety and benefits are unknown.
Technical definition
KLOW is a research-market, fixed-ratio blend of four peptides: BPC-157 (a 15-amino-acid gastric pentadecapeptide), TB-500 (a thymosin beta-4 fragment that binds actin and promotes cell migration), GHK-Cu (a copper-binding glycyl-histidyl-lysine tripeptide that modulates collagen synthesis and tissue-repair genes) and KPV (the Lys-Pro-Val C-terminal tripeptide of alpha-MSH that inhibits NF-kB inflammatory signaling). It is the GLOW blend plus KPV. Each component has been studied separately, mostly in animals and cells; the combination has no clinical trials and is not FDA-approved.
Function
Dosing
Recommended Time of Day
Evening is common in community use; no studied time of day.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
- Flank / love handle — Lateral fat pad above the hip. Good rotation site when the abdomen is tender.
- Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
No evidence-based cycle exists. Community protocols commonly run 8–12 weeks followed by about 4 weeks off; this is anecdotal.
Timing & Interactions
- ·Active or suspected cancer — several components promote blood-vessel growth
- ·Taking BPC-157, TB-500, GHK-Cu or KPV separately at the same time — doubles up the same ingredients
- ·High-dose vitamin C at the same moment as GHK-Cu — may disturb the copper complex
- ·Clinician-guided wound, skin or physical-therapy care
- ·Gentle skincare and sun protection
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV) and sync them to Vial Lab.
Benefits
- ·Faster wound and tendon healing in animal studies (BPC-157, TB-500)
- ·Collagen and skin-repair gene activity (GHK-Cu, mostly cell and topical data)
- ·Reduced gut and skin inflammation in animal models (KPV)
- ·Single injection replaces four separate vials
Risks
- ·No human safety data for the combination
- ·Fixed ratio — a reaction cannot be traced to one ingredient, and doses cannot be adjusted separately
- ·Injection-site stinging or blue-tinged welts from copper (GHK-Cu)
- ·Theoretical concern with cancer because several components promote blood-vessel growth
- ·Research-chemical supply — purity, sterility and labeled amounts often unverified
Contraindications
- ·Active cancer or history of cancer
- ·Pregnancy or breastfeeding
- ·Wilson's disease or copper sensitivity
- ·Competitive athletes subject to WADA testing
- ·Under 18 years of age
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- ·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- ·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
Not FDA-approved in any form. FDA placed BPC-157 and thymosin beta-4 fragments on its compounding Category 2 list (significant safety concerns), so compounding pharmacies generally cannot supply them. TB-500 is WADA-prohibited; the other components may fall under WADA's non-approved substances clause.
Veterinary Use (Pets)
No established veterinary protocol for KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV). Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Cited Works
Tap any study to open the published work.
- 1.Sikiric P et al. BPC 157, a body protection compound: review. Curr Pharm Des. 2018;24:1990-2001.Read published work Link not opening? Search Google Scholar
- 2.Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110:774-80.Read published work Link not opening? Search Google Scholar
- 3.Goldstein AL et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12:37-51.Read published work Link not opening? Search Google Scholar
- 4.Malinda KM et al. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999;113:364-8.Read published work Link not opening? Search Google Scholar
- 5.Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19:1987.Read published work Link not opening? Search Google Scholar
- 6.Pickart L et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108.Read published work Link not opening? Search Google Scholar
- 7.Luger TA et al. New insights into the functions of α-MSH and related peptides in the immune system. Ann N Y Acad Sci. 2003;994:133-40.Read published work Link not opening? Search Google Scholar
- 8.Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134:166-78.Read published work Link not opening? Search Google Scholar
- 9.Xiao B et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017;25:1628-40.Read published work Link not opening? Search Google Scholar
- 10.U.S. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 list, includes BPC-157 and thymosin beta-4 fragments).Read published work Link not opening? Search Google Scholar
- 11.World Anti-Doping Agency. Prohibited List (S0 non-approved substances; S2 includes thymosin β4 and derivatives).Read published work Link not opening? Search Google Scholar